✦ LIBER ✦

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

✍ Scribed by Glen J. Weiss, Manuel Hidalgo, Mitesh J. Borad, Daniel Laheru, Raoul Tibes, Ramesh K. Ramanathan, Lisa Blaydorn, Gayle Jameson, Antonio Jimeno, Jeffrey D. Isaacs, Angela Scaburri, Maria Adele Pacciarini, Francesco Fiorentini, Marina Ciomei, Daniel D. Von Hoff

Book ID: 118299070
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 393 KB
Volume: 30
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-011-9774-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preliminary results of an ongoing phase

Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 140 KB

A first-in-man phase I tolerability and

A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

✍ D. Ross Camidge; Dominic Smethurst; Jim Growcott; Nigel C. Barrass; John R. Fost 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 324 KB

Phase I Study of GSK461364, a Specific a

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

✍ Olmos, D.; Barker, D.; Sharma, R.; Brunetto, A. T.; Yap, T. A.; Taegtmeyer, A. B 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 988 KB

Phase I safety, pharmacokinetic, and pha

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

✍ Markman, B.; Tabernero, J.; Krop, I.; Shapiro, G. I.; Siu, L.; Chen, L. C.; Mita 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 362 KB

A Phase I study to assess the safety, to

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

405 POSTER A phase I dose-escalation stu

405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies

✍ R. Kurzrock; L. Camacho; D. Hong; C. Ng; L. Janisch; M.J. Ratain; R. Salgia 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 90 KB